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CYLD regulates keratinocyte differentiation and skin
cancer progression in humans
JP Alameda1, MJ Fernández-Aceñero2, R Moreno-Maldonado1, M Navarro1, R Quintana1, A Page1, A Ramı́rez1, A Bravo3
and ML Casanova*,1
CYLD is a gene mutated in familial cylindromatosis and related diseases, leading to the development of skin appendages tumors.
Although the deubiquitinase CYLD is a skin tumor suppressor, its role in skin physiology is unknown. Using skin organotypic
cultures as experimental model to mimic human skin, we have found that CYLD acts as a regulator of epidermal differentiation in
humans through the JNK signaling pathway. We have determined the requirement of CYLD for the maintenance of epidermal
polarity, keratinocyte differentiation and apoptosis. We show that CYLD overexpression increases keratinocyte differentiation
while CYLD loss of function impairs epidermal differentiation. In addition, we describe the important role of CYLD in the control
of human non-melanoma skin cancer progression. Our results show the reversion of the malignancy of human squamous cell
carcinomas that express increased levels of CYLD, while its functional inhibition enhances the aggressiveness of these tumors
which progress toward spindle cell carcinomas. We have found that the mechanisms through which CYLD regulates skin cancer
progression include the control of tumor differentiation, angiogenesis and cell survival. These findings of the role of CYLD in
human skin cancer prognosis make our results relevant from a therapeutic point of view, and open new avenues for exploring
novel cancer therapies.
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The epidermis is a stratified squamous epithelium composed
mainly of keratinocytes. Basal keratinocytes proliferate and
give rise to differentiated cells, which, upon full maturation,
undergo enucleation and generate the squamous cornified
layer.1 Several molecules have been found to develop
important roles in this differentiation process. Among them,
the c-Jun-NH2-terminal kinase (JNK) signaling pathway has
an emergent role,2,3 as the inhibition of JNK activity in
keratinocyte induces epidermal differentiation (stratification
and production of cornified envelopes), while augmented JNK
activity delays or inhibits keratinocyte differentiation.2 To be
functional, keratinocytes must also maintain an apico-basal
polarization, b-catenin being an important molecule to the
generation of a polarized epithelial phenotype;4,5 that is,
perturbed b-catenin location (cytoplasmic localization and
reduced membranous expression) is associated to lack of
differentiation, invasive potential and aggressive behaviour6
in tumors. Disturbances of the balance proliferation/
differentiation/apoptosis of the epidermis result in epidermal
disorders, such as hyperplasia, psoriasis and skin cancer.
Non-melanoma skin cancers (NMSC): basal cell carcinomas
(BCC) and squamous cell carcinomas (SCC) are the most
common human malignancies.
CYLD is a tumor suppressor gene that was originally
identified as a gene mutated in familial cylindromatosis, a
genetic condition that predisposes patients for the develop-
ment of skin appendages tumors.7 CYLD deubiquitinating
activity removes lysine-63 polyubiquitin chains.7 Most of the
mutations within the CYLD locus are located toward the
carboxyl terminus of the protein, the position of the catalytic
residues of ubiquitin hydrolase.8,9 Depending on the cellular
context CYLD negatively regulates NF-kB and/or JNK-
signaling pathways, resulting in suppression of cell prolifera-
tion.10–13 In keratinocytes, JNK activation promotes cell
proliferation and inhibits differentiation,2 whereas NF-kB
appears uninvolved in epidermal differentiation.14,15
Besides its role in the familial cylindromatosis, additional
studies have associated CYLD downregulation with the
development of other types of human cancer including tumors
of colon, lung and kidney, as well as melanomas and cervical
and hepatocellular carcinomas.16–20 Recently, we have
demonstrated a relationship between the inhibition of CYLD
function and an increase in aggressiveness of mouse
NMSC.21 However, although CYLD is ubiquitously expressed
and its function as tumor suppressor is being actively
investigated, little is known about its role in the homeostasis
of the different tissues; particularly in the skin.
In this study we have analyzed the role of CYLD in the
homeostasis and carcinogenesis of human skin. We have
used skin organotypic cultures (also named skin equivalents)
as experimental model to mimic human skin in vitro. Similar to
the epidermis, the epithelium of the skin organotypic culture
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stratifies and differentiates. This model has allowed us to
increase the expression or to inhibit the function of CYLD in a
human-like context. As a result, we have found that forced
expression of wild-type CYLD (CYLDWT) both in HaCaT
keratinocytes and in the skin equivalents enhances keratino-
cyte differentiation, while the inhibition of CYLD function by
expression of a catalytically inactive form of CYLD impairs
epidermal differentiation. CYLDWT overexpression is also
able to induce the differentiation of human A431 squamous
carcinoma (SCC) cell line. Our results show that CYLD
controls skin differentiation through the JNK signaling path-
way. In addition, using an in vivo xenograft model of skin
carcinogenesis, we describe the important role of CYLD in the
control of human NMSC progression.
Results
Forced expression of CYLDWT in human keratinocytes. The
HaCaT cell line, a non-tumoral immortalized human epidermal
cell line commonly used in epidermal biology studies,22 was
employed. HaCaT cells maintain full epidermal differentiation
capacity: when cultured in the absence of serum, they form
stratification domes and express the early differentiation marker
keratin K10.22 Moreover, they are able to grow in organotypic
cultures.23 HaCaT cells were stably transfected with the
CYLDWT cDNA under the control of the b-actin promoter
(b-actin-CYLDWT) or with the empty vector. Pooled stable
transfectants carrying either construct were used to minimize
any potential effect of clonal selection. They were designated as
H-CYLDWT and H-control cells (expressing the CYLDWT
transgene and the empty vector, respectively). Western
blotting against CYLD showed that H-CYLDWT cells had
increased levels of CYLD (Figure 1a) compared with the
endogenous levels of CYLD in the H-control cells.
Increased CYLDWT expression enhances the
differentiation of human keratinocytes in culture. We
analyzed the differentiation properties of H-control and
H-CYLDWT cells. By day 7 of growth in absence of serum
all the H-CYLDWT pools of cells showed well-formed
stratification domes, while in H-control cells the first (still
rudimentary) domes were detected at day 14 (Figure 1b).
The analysis of the early differentiation marker keratin K10,
not expressed in undifferentiated cells, shows that at day 6 of
differentiation the H-CYLDWT cells showed very high levels of
K10, while the H-control cells did not show these levels of
K10 expression until day 13 of differentiation (Figure 1c).
Abundant cell death was observed in the supernatants of
both, differentiated and conventional H-CYLDWT monolayer
cultures; the analysis of the pro-apoptoctic protein
Bax showed that it was highly expressed in the H-CYLDWT
cells compared with the low levels of expression found in the
H-control cells (Figure 1d). Moreover, after UV light
stimulation (an inductor of apoptosis in keratinocytes),24
Bax was highly induced in the H-CYLDWT cells (Figure 1d).
Therefore, our results indicate that H-CYLDWT cells are
prone to differentiation in addition to presenting a high rate of
apoptosis.
Figure 1 Properties of transfected HaCaT CYLD cells. (a) Western blot showing CYLD overexpression in one of the H-CYLDWT pools (H-Co, H-Control cells). Tubulin was
used as loading control. (b) H-control and H-CYLDWT cells differentiation cultures. Red circles: stratification domes (c) (top) keratin K10 RNA levels in H-control and H-CYLDWT
cells detected by northern blotting at the stated times (days); 7S, loading control. (bottom) Graphical representation of the northern blotting signals relative to those of loading
controls (arbitrary units). The difference in K10 content between cells of both genotypes is statistically significant at 6, 10 and 13 days of differentiation. (d) Western blot of
proteins from H-control, H-CYLDWT and H-CYLDC/S cells in the basal state or after UV stimulation showing an increase in JNK activation in the H-CYLDC/S cells and a
reduction in the H-CYLDWT. Analysis of Bax expression. Actin was used as loading control. Western blots were performed 3–4 times
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Increased CYLD expression enhances the differentiation
of keratinocytes in human skin equivalents. Organotypic
skin cultures were established with both H-control and
H-CYLDWT cells. H-control skin (6-day) equivalents were
composed by 3–4 layers of keratinocytes distributed in well
distinguishable strata: a basal layer with cylindrical cells
of large nuclei; 1–2 layers of suprabasal cells of small
nuclei and a superficial stratum containing flattened cells
with the nuclei parallel to the basal membrane (Figure 2a).
More engrossed epithelium was found in the H-CYLDWT
skin equivalents that contain 6–7 layers of keratinocytes,
including higher number of flattened suprabasal cells (3–4
layers), which suggested an increased differentiation
(Figure 2c). According to these histological characteristics,
the differentiation marker keratin K1 was widely expressed
in the 6-day H-CYLDWT skin equivalents, (Figure 2d)
whereas there was scarce K1 expression in 6-day-H-
control organotypic cultures (Figure 2b). By 12 days of
growth in air–liquid interface, H-control skin equivalents
showed increased stratification (with respect to that
observed at 6 days of culture), showing a higher number of
suprabasal cells containing abundant cytoplasm and
some apoptotic cells (Figure 2e). By this time point,
CYLDWT organotypic cultures also have increased their
number of suprabasal cells, and strikingly, there were
very high number of apoptotic cells (Figure 2g). Cleaved
caspase 3 staining confirmed the abnormally high number of
apoptotic cells present in the suprabasal and the
intermediate cell layers of H-CYLDWT skin equivalents
(Figures 2f and h).
The decreased JNK pathway activation in the H-CYLDWT
cells appears as a plausible mechanism for CYLD
induction of keratinocytes differentiation. JNK signaling
is a relevant pathway for keratinocyte differentiation and it is
negatively regulated by CYLD.13 The analysis of JNK
phosphorylation (activation) in H-CYLDWT cells showed
decreased activation of JNK with respect to that of
H-control cells in the non-stimulated state (Figure 1d,
middle row). No differences were found between H-control
and H-CYLDWT cells in response to UV stimulation
(Figure 1d). Our results showing increased differentiation of
the H-CYLDWT cells that present a diminished JNK
activation, are in agreement with the previous studies
reporting increased keratinocyte differentiation as a
consequence of JNK activity inhibition.2
The inhibition of CYLD function in keratinocytes
enhances the activation of the JNK pathway. To further
confirm the CYLD function as regulator of keratinocyte
differentiation and the relevance of the JNK pathway
activation as a mechanism through which it may exerts its
function, we generated HaCaT cells expressing a
catalytically deficient CYLD mutant (CYLDC/S) that carries
the 601C/S point mutation in the cysteine box of the
deubiquitinase.10 The expression of this transgene results
in a catalytically inactive protein that competes with the
endogenous CYLD.10,12,20,21,25 HaCaT cells were stably
transfected with CYLDC/S cDNA under the control of the
b-actin promoter or with the empty vector, and different pooled
stable transfectants were collected (designated as H-CYLDC/S
and H-control cells). Western blot analysis showed increased
levels of CYLD in the H-CYLDC/S cells (Figure 3a).
We proved the lack of deubiquitination function of CYLD in
the H-CYLDC/S cells (Figure 3b). We then studied the JNK
activation pathway in the H-CYLDC/S cells. Both H-control and
H-CYLDC/S cells were UV-irradiated and JNK activation in
response to irradiation was analyzed. We found that JNK was
highly activated after UV stimulation in the H-CYLDC/S cells
(Figure 1d). Therefore, our results show that in human
keratinocytes the activation of JNK pathway was increased
by the functional inhibition of CYLD while, consistently, it was
diminished by the overexpression of CYLDWT (Figure 1d).
The diminished function of CYLD impairs the
differentiation of keratinocytes in human HaCaT skin
equivalents. H-CYLDC/S skin equivalents were established.
By 10 days of air-phase growth, H-control organotypic
cultures formed a well-arranged tissue structure (Figure 3c)
with a basal layer formed by cylindrical cells of large nuclei
and 4–6 layers of suprabasal cells, being the most superficial
flattened cells with small nuclei in parallel to the basal
membrane (Figure 3c). In contrast, 10-days H-CYLDC/S skin-
equivalents showed a higher number of cell layers than the
H-control skin equivalents, presenting heterogeneity in size,
shape and orientation of the nuclei, resembling a
disorganized epidermis with loss of cell polarity (Figure 3d).
Cells invading the subjacent matrix were also frequently seen
in the H-CYLDC/S skin equivalents (Figures 3e and j). To
ascertain the possible cause of the loss of cell polarity
observed in the CYLDC/S keratinocytes, we analyzed the
Figure 2 Increased differentiation and apoptosis in H-CYLDWT skin equivalents.
(a–d) Skin (6-day) equivalents showing increased differentiation of H-CYLDWT
organotypic cultures by histological examination (a and c) and by K1 staining
(b and d). Arrow in (a): example of stratified cell; sl, suprabasal layers. (e–h) Skin
(12-day) equivalents showing increased apoptosis in the H-CYLDWT skin
equivalents by histological observation (e and g) and by anticleaved caspase 3
staining (C3C) (f and h). Arrows in e and g: apoptotic nuclei
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expression of b-catenin, as this is a relevant protein for the
generation of a polarized epithelial phenotype.4,5 We found a
normal, membranous localization of b-catenin at the cell–cell
contacts of almost all the cell layers in both H-control and
H-CYLDWT skin equivalents (Figure 3k); by contrast,
H-CYLDC/S skin equivalents showed a disorganized
b-catenin location, that even was absent in most of the
suprabasal cells (Figure 3k). Even more, we also found that
in H-CYLDC/S monolayer cultures, b-catenin appeared
forming dots or diffusely distributed in the cytoplasm of
most of the cells (Figure 3l), in sharp contrast with the
membranous pattern of b-catenin staining at the cell–cell
contacts found in both H-control and H-CYLDWT cells.
To analyze the differentiation of both the H-CYLDC/S and
H-control skin-equivalents, we studied the expression of
involucrin, a marker of early differentiation. We found an
extensive staining in the suprabasal layers of H-control
organotypic cultures (Figure 3f). However, H-CYLDC/S skin
equivalents only showed a very scarce involucrin staining,
indicating their lack of differentiation (Figure 3g).
Cleaved caspase 3 immunostaining showed an important
reduction in the number of apoptotic cells in H-CYLDC/S
organotypic cultures (Figures 3i and j), compared with
H-control skin equivalents (Figure 3h), suggesting that
CYLDC/S confers protection against cell death by apoptosis
in human keratinocytes. Remarkably, these features found in
H-CYLDC/S skin equivalents, that is, loss of cell polarity,
altered b-catenin distribution, lack of differentiation, presence
of invasion foci and cell resistance to apoptosis, are
alterations that could evolve to epithelial dysplasia and pre-
malignant changes.
Generation of human A431 squamous carcinoma
cells expressing increased levels of CYLDWT or the
catalytically inactive CYLDC/Smutant. To investigate the
role of CYLD in the progression of human skin cancer, we
generated A431 cells expressing the b-actin-CYLDWT and
b-actin-CYLDC/S constructs (Figure 4a; Supplementary
Information SI-1a). They were designated as A-CYLDWT,
A-CYLDC/S and A-control cells. We checked that the
Figure 3 Functional analysis of H-CYLDC/S cells. (a) Western blot showing CYLD overexpression in two H-CYLDC/S pools (C/S 1 and C/S 2). (b) Deubiquitination of IKKg/
NEMO (by CYLD) in H-control and H-CYLDC/S cells before (0) or after (300 and 600) TNF-a stimulation. IKKg-immunoprecipitated samples were probed with an antiubiquitin
antibody (upper panel) then reprobed with an antibody against IKKg (lower panel). Observe that TNF-a stimulation failed to increase the polyubiquitination of IKKg in the H-
control cells. By contrast, TNF-a stimulation resulted in significant polyubiquitination of IKKg in the H-CYLDC/S cells. (c–e) Hematoxylin/eosin staining of 10-day skin
equivalents showing the altered morphology of H-CYLDC/S skin equivalents (d and e) versus H-control organotypic cultures (c); arrows in (e and j): foci of invasion. (g)
Impaired differentiation of H-CYLDC/S organotypic cultures as studied by involucrin (invol) staining compared with the differentiated H-control skin equivalents (f). (i–j) Cleaved
caspase 3 (C3C) immunostaining showing the resistance to apoptosis of the H-CYLDC/S skin equivalents compared with H-control organotypic cultures (h). (k and l) b-catenin
expression in H-control, H-CYLDWT and H-CYLDC/S keratinocytes growing as monolayers (l) or in the skin equivalents (k)
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A431-CYLDC/S cells have impaired the CYLD
deubiquitination activity (Supplementary Figure SI-1b).
Increased CYLDWT expression in the A431 human
squamous carcinoma cells induces a differentiated
phenotype of the cells in vitro and an increase in cell
death by apoptosis. Stratification domes were formed in
conventional cultures of A-CYLDWT cells (Figure 4b),
suggesting the spontaneous differentiation of the
A-CYLDWT cells. The presence of K10 staining in the
A-CYLDWT cells and its absence in both, A-control and
A-CYLDC/S cultures, confirmed their more differentiated
phenotype (Figure 4c). Additionally, abundant dead cells
were found in the supernatants of A-CYLDWT cells coincident
with elevated levels of expression of the pro-apoptotic protein
Bax, while low expression or absence of Bax were detected
in A-control and A-CYLDC/S cells, respectively (Figure 4a).
JNK activity is enhanced in A-CYLDC/S cells and
inhibited in A-CYLDWTcells. We analyzed the JNK
pathway and found that in the non-stimulated state, the
A-CYLDC/S cells presented an enhanced JNK activity
(Figure 4d). In addition, A-CYLDC/S cells also showed
increased levels of P-JNK upon TNF-a stimulation. On the
contrary, CYLDWT overexpression leads to a diminished JNK
activation both in non-stimulated and in TNF-a-stimulated
A-CYLDWT cells (Figure 4d). The fact that the overexpression
of CYLD in A431 cells and its functional inactivation lead to
opposite effects in JNK activation, reinforces the relevance of
this signaling pathway as mediator of CYLD functions in the
A431 cells and is in agreement with the results found in the
HaCaT keratinocytes.
Increased CYLDWT expression in human squamous
carcinoma cells improves the malignant phenotype of the
SCCs while CYLDC/S enhances their aggressiveness. We
performed xenograft carcinogenesis assays of the A431 cells.
A-control, A-CYLDWT and A-CYLDC/S cells were injected into
nude mice. The latency of macroscopic tumor appearance was
similar, approximately 1 week, in the three cases (data not
shown). Histologically, A-control tumors were solid SCCs and
poorly differentiated (Figures 5a–c). By contrast, tumors
originated from A-CYLDWT were of better prognosis as in
addition to poorly differentiated areas, they exhibit extensive
regions of necrosis in the core of the tumor (Figures 5d–f);
moreover, we also found A-CYLDWT tumors consisting of
benign cysts (Figures 5g–i). These features are compatible with
the regression of the tumor. On the other hand, A-CYLDC/S
tumors showed worse prognosis than A-control tumors, as they
were anaplastic SCCs with high grade of cellular atypia and
fusocellular morphology, resembling sarcomas or spindle-cell
carcinomas (Figures 5j–k).
The immunohistochemical analysis showed increased
expression of CYLD in both A-CYLDWT and A-CYLDC/S
tumors compared with the expression in A-control SCCs
(Figure 6). Low levels of expression of keratins K10 and K1 –
reliable markers of well-differentiated tumors– were noted in
A-control andA-CYLDWTSCCs, and theywere not detected in
A-CYLDC/S carcinomas (Figure 6 and data not shown).
Keratin K8, a marker of malignancy in skin tumors26 showed
extensive staining in both A-control and A-CYLDC/S carcino-
mas, while it was scarcely expressed in A-CYLDWT tumors
(Figure 6). K5 is a keratin typical of stratified epithelial tissues,
expressed by normal skin and skin tumors that are lost in the
later stages of tumor progression, that is, in spindle cell
carcinomas. In agreement to their spindle-like phenotype,
A-CYLDC/S tumors exhibited areas lacking K5 expression
(Figure 6). CD31 staining analysis of tumor blood vessels
showed a network of large and lacunar vessels in A-CYLDC/S
tumors while those found in A-CYLDWT were predominantly
small and narrow; blood vessels developed in
A-control carcinomas had an intermediate lumen diameter
(Figures 7a–c). The analysis of a-smooth muscle actin (SMA),
a marker of smooth muscle cells and pericytes, showed a
discontinuous expression in the A-CYLDC/S tumors indicating
the immature and leaky nature of the blood vessels
(Figure 7f). By contrast, the vessels of the A-CYLDWT tumors
were strongly stained demonstrating a mature and imperme-
able vascular phenotype (Figure 7d). A-control tumors
presented weak SMA staining although predominantly in a
continuous way (Figure 7e). Therefore, the vasculature
analysis indicates an increased angionesis in A-CYLDC/S
SCCs and consequently, poor prognosis. Finally we also
check that A-CYLDWT tumors were prone to undergo
apoptosis (SI-2).
Figure 4 Characterization of A-CYLDWT and A-CYLDC/S cells. (a) Western blot
analysis of CYLD and Bax expression in total protein extracts from A431 cells of the
three genotypes. (b) Monolayer culture of A-control, A-CYLDWT and A-CYLDC/S
cells. Red circles: foci of spontaneous differentiation. Note the scattered phenotype
of A-CYLDC/S cells and its loose growth in culture. (c) Immunofluorescence showing
expression of K10 in A-CYLDWT cells. (d) Western blot of protein extracts from A-
control, A-CYLDWT and A-CYLDC/S cells in unstimulated or after UV stimulation.
Note the increase in JNK activation in A-CYLDC/S cells and the reduction in the
A-CYLDWT cells
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Discussion
Here we describe that CYLD acts as regulator of epidermal
differentiation in humans. Our data demonstrate that altera-
tions in CYLD expression in keratinocytes disrupt normal
epidermal homeostasis: the forced expression of CYLDWT in
human HaCaT keratinocytes and the skin equivalents
enhance keratinocyte differentiation. By contrast, the expres-
sion of a mutant CYLDC/S that inhibits the endogenous CYLD-
deubiquitination function impairs keratinocyte differentiation.
We have found that JNK signaling pathway could be
mediating the effects of CYLD in epidermal differentiation. In
fact, it was previously reported that the inhibition of JNK
activation in keratinocyte cultures in vitro induces almost all
aspects of epidermal differentiation in vivo, including stratifi-
cation and even production of cornified envelopes.2 By
contrast, augmented JNK activity delays or inhibits keratino-
cyte differentiation.2 In line with these results, we have found
diminished JNK activation in keratinocytes expressing
CYLDWT, concomitant with an enhanced epidermal differ-
entiation of the CYLDWT skin equivalents; additionally, we
have found increased JNK activation in the CYLDC/S
keratinocytes associated to an impaired epidermal differentia-
tion of the CYLDC/S skin equivalents. This finding is relevant
for our understanding of both the normal epidermal differ-
entiation and its perturbations during pathological conditions.
Importantly, we have discovered that CYLDWT also
promotes the differentiation of A431 tumoral keratinocytes
through inhibition of JNK activation. It may be significant
clinically, because attenuating JNK activity could become a
differentiation therapy-based approach for skin cancer in
general and for tumors developed by familial cylindromatosis
patients in particular.
Another finding of this study is the increased rate of
apoptosis induced by CYLDWT both in tumoral and non-
tumoral human keratinocytes. This effect could be the
consequence of the lack of JNK-mediated cell survival
signaling due to the diminished JNK activation in these
cells.27 Our present results showing increased apoptosis in
cells, and importantly, in skin tumors overexpressing
CYLDWT, constitute an important finding for the identification
of the mechanisms through which CYLD exerts its role as a
tumor suppressor.
In addition to the impairment of keratinocyte differentiation,
we have found that CYLDC/S expression provokes other
alterations in skin equivalents such as the loss of cell polarity,
Figure 5 Hematoxilin/eosin staining of A-control, A-CYLDWT and CYLDC/S tumors. (a–c) A-control tumors are solid undifferentiated SCCs. (d–f) A-CYLDWT tumors
contain large cavities as a result of tumor degeneration (arrow in d) (g–i); often they also form cystic, differentiated structures. (j–k) A-CYLDC/S SCCs are spindle-shape
tumors. Compare the cords of fibroblasts-like cells forming the mutant tumors with the keratinocytes of the A-control SCCs (c). Tumors (10–12) of each type were analyzed
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likely due to the loss of b-catenin membranous distribution
and its cytoplasmic accumulation. Maintenance of cell
polarity is an essential requirement for the functionality and
homeostasis of epithelial tissues, being b-catenin a key
molecule in the maintenance of epithelial architecture as it
regulates the polarity of cells and tissues.28 Other features of
the H-CYLDC/S skin equivalents are the formation of foci of
basal invasion and resistance to apoptosis. Altogether, these
changes could lead to epithelial dysplasia and reflect pre-
malignant modifications, such as loss of epithelial differentiation
and cell polarity, and the acquisition of invasive properties are
frequently observed in malignant transformation. According to
these pathological alterations found in H-CYLDC/S skin equiva-
lents, CYLDC/S expression in A431 squamous carcinoma cells
Figure 6 Immunocharacterization of A-control, A-CYLDWT and A-CYLDC/S tumors. Staining with specific antibodies against CYLD, K10, K8 and K5. The increased K8
expression in the A-CYLDC/S tumors, together with lack of K5 and K10 staining are indicative of an aggressive phenotype. Tumors (10–12) of each type were analyzed
Figure 7 CYLDWT expression decreases tumor angiogenesis, while loss of CYLD function enhances the vascularization of skin tumors. (a–c) CD31 staining of blood
vessels. Note the smaller size of the vessels in the A-CYLDWT tumors compared with that of A-CYLDC/S SCCs. (d–f) SMA staining. Representative tumors are shown in each
panel. Similar data were obtained in five tumors of each genotype. Arrows in (e) indicate the blood vessels. Arrowheads in (f) mark the extremes of the blood vessels. Six
tumors of each type were analyzed
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induces an enhancement of their malignancy in carcinogenesis
assays.
Several mechanisms have been proposed through which
loss of CYLD may exert a role in tumor promotion. One of
them is the hyperactivation of antiapoptotic signals in absence
of functional CYLD in tumoral cells;29 previously we described
that CYLDC/S induced resistance to apoptosis in mouse skin
tumors;21 here we also extend this property to human skin
cancer. We have also showed that CYLDC/S expression
enhances angiogenesis in mouse skin carcinomas,21 what
constitutes a prominent feature of skin tumor progression.30
Here we have also confirmed that in human SCCs CYLDC/S
expression leads to a strong angiogenesis, increasing the size
and permeability of blood vessels. Importantly, we have found
as well that CYLDWT overexpression in SCCs reduces the
diameter of the blood vessels and augments its maturity,
which possibly make them unable to supply the nutrients
needed for tumor progression.
Therefore our study is relevant because it established the
role that CYLD has in normal skin physiology. The use of our
skin equivalent model has allowed us to determine the
importance of CYLD for the maintenance of epidermal
polarity, keratinocyte differentiation and apoptosis. In addi-
tion, our results show the reversion of the malignancy of the
SCCs that express increased levels of CYLDWT. The increase
in apoptotic cell death of the A-CYLDWT tumors, together with
the reduced angiogenesis could be responsible of the
A-CYLDWT tumor regression observed in the carcinogenesis
assays. Accordingly, SCCs defective in CYLD function are
very aggressive as revealed by their progression toward
spindle cell carcinomas, resistance to apoptosis and
increased angiogenesis. These findings of the in vivo
influence of CYLD in cancer prognosis make our results
relevant from a therapeutic point of view, and open new
avenues for exploring novel cancer therapies.
Materials and Methods
DNA constructs. CYLDC/S cDNA was kindly provided by Dr. R Bernards and
subcloned under the control of b-actin promoter.21 b-actin-control construct has
been described.21
Cells and culture conditions. HaCaT and A431 cells were cultured
in DMEM and 10% FCS. Cells were permanently transfected using the calcium
phosphate method. In all transfections, the corresponding empty vectors were used
as controls. Resistant colonies were selected using G418 and pooled (each pool
was formed from approximately 20 different colonies). To allow HaCaT in vitro
differentiation, cells were seeded and after reaching 60–80% confluence were
grown in culture medium without FCS for different days.22 Experiments were
performed with 2–3 different pools of transfected cells of each genotype.
TNF-a and UV stimulation. When required, cells were treated with human
TNFa (50 ng/ml; Sigma, Saint-Louis, Missouri, USA) or irradiated with UVB for the
indicated times. For UVB irradiation, a Waldmann lamp (UV236B, TECNOSA,
Nuevas Tecnologı́as SA, Barcelona, Spain)) was used. The light emitted was within
the UVB range (280–320 nm), with a peak emission at 312 nm. HaCaT cells in PBS
were irradiated with 800 mJ/cm2 dose of UVB for 2 min. After irradiation, the cells
were put in pre-warmed medium (371C) and collected 3 hs after irradiation.
Immunoblots. Antibodies used were: Actin, Bax, P-JNK, CYLD, tubulin
(Sigma); ubiquitin (Cell Signaling Technology, Danvers, MA, USA); IKKg/NEMO
(IMGENEX, San Diego, CA, USA). For immunoprecipitation, total lysates were
obtained from untreated or TNFa-treated (50 ng/ml; Sigma) HaCaT and A431 cells.
A total of 300mg of lysate were immunoprecipated with and the anti-IKKg antibody
and resolved on an SDS gel; probed with an antiubiquitin antibody, then stripped
and reprobed with an antibody against IKKg (to show the amounts of IKKg
immunoprecipitated).
Skin equivalents preparation. Human dermal fibroblasts were obtained
according to Meana et al.31 To generate skin equivalents, 1.5 ml of fibrinogen
solution (from cryoprecipitated pig blood) was added to 5 ml of keratinocyte growth
medium containing 2.5 105 dermal fibroblasts. Immediately after that, 0.5 ml of
0.025 mM Cl2Ca, with 5.5 IU of bovine thrombin (Sigma-Aldrich Co., St. Louis, MO,
USA) was added. The mixture was then placed on polycarbonate inserts (4mM
porous) in a six-well culture plate (Corning Costar Corp., Cambridge, MA, USA) and
allowed to solidify at 37 1C for 2 h; 106 HaCaT cells were seeded on the fibrin matrix
and grown to confluence. After 48 h of seeding, organotypic cultures were raised to
the air–liquid interface for 6–12 days to achieve epidermal stratification.
Northern blotting. Total RNA was isolated by Trizol extraction (Gibco-BRL,
San Francisco, CA, USA) following the manufacturer’s instructions; 10 mg/lane RNA
were probed for the expression of keratin K10.22 A ribosomal 7S RNA probe was
used as a loading control.
Xenograft model of carcinogenesis. Tumors were induced in nude mice
(Hsd-Athymic Nude, Harlan Europe, Barcelona, Spain) by subcutaneous flank
inoculation of 106 A431 control, CYLDWT or CYLDC/S cells. In all, 6–8 mice were
inoculated in both flanks with each type of cells. Tumors were harvested 18 days
post-cell injection. Experimental procedures were performed according to European
and Spanish laws.
Histology and immunohistochemistry. Skin equivalents were fixed in
formalin and embedded in paraffin. A431 tumors were fixed in methanol/acetone
(1/1); in 70% ethanol or in formalin. Sections were stained with H&E for
histopathological evaluation. Cells and tissue sections were stained with antibodies
against keratins K1 (Covance, San Diego, CA, USA); K8, K10, involucrin and SMA
(Sigma-Aldrich); b-catenin, CD31 (BD Biosciences, San Diego, CA, USA) and
cleaved caspase 3 (Cell Signaling Technology).
Immunofluorescence. Cells were fixed in methanol/acetone (1/1). Alexa
Fluor-594 goat antimouse IgG(Hþ L) (Life Technologies SA, Paisley, UK) was used
as fluorochrome.
Statistics. Statistical significance of data was assessed using the t-test and the
Mann–Whitney (Wilcoxon) W test.
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